Equities research analysts at Barclays PLC assumed coverage on shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) in a report released on Wednesday. The brokerage set an “overweight” rating and a $20.00 price target on the biopharmaceutical company’s stock. Barclays PLC’s price target suggests a potential upside of 33.33% from the stock’s previous close.

Several other brokerages have also weighed in on SGMO. Jefferies Group LLC restated a “buy” rating and issued a $18.00 price objective on shares of Sangamo Therapeutics in a report on Friday, October 13th. Wedbush restated a “hold” rating and issued a $6.00 price objective on shares of Sangamo Therapeutics in a report on Wednesday, November 15th. Wells Fargo & Company restated an “outperform” rating and issued a $30.00 price objective (up from $20.00) on shares of Sangamo Therapeutics in a report on Tuesday, September 5th. Zacks Investment Research upgraded shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a report on Wednesday, November 15th. Finally, Piper Jaffray Companies upgraded shares of Sangamo Therapeutics from a “neutral” rating to an “overweight” rating and set a $19.00 price objective on the stock in a report on Wednesday, November 15th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. Sangamo Therapeutics currently has a consensus rating of “Buy” and an average target price of $17.83.

Sangamo Therapeutics (NASDAQ SGMO) opened at $15.00 on Wednesday. Sangamo Therapeutics has a 12-month low of $2.65 and a 12-month high of $17.06. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.64 and a current ratio of 5.64.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.04. Sangamo Therapeutics had a negative net margin of 157.66% and a negative return on equity of 31.81%. The company had revenue of $11.81 million for the quarter, compared to analyst estimates of $10.37 million. During the same period in the prior year, the business earned ($0.27) earnings per share. Sangamo Therapeutics’s quarterly revenue was up 333.0% on a year-over-year basis. equities analysts forecast that Sangamo Therapeutics will post -0.79 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/11/24/sangamo-therapeutics-inc-sgmo-now-covered-by-barclays-plc.html.

In other news, VP Curt A. Herberts III sold 15,000 shares of the stock in a transaction on Friday, September 1st. The shares were sold at an average price of $15.00, for a total transaction of $225,000.00. Following the completion of the sale, the vice president now owns 15,833 shares of the company’s stock, valued at $237,495. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director William R. Ringo sold 31,000 shares of the stock in a transaction on Wednesday, September 20th. The stock was sold at an average price of $14.37, for a total transaction of $445,470.00. Following the sale, the director now directly owns 31,800 shares of the company’s stock, valued at approximately $456,966. The disclosure for this sale can be found here. Insiders sold 66,000 shares of company stock valued at $972,570 in the last ninety days. Insiders own 5.50% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. Neuberger Berman Group LLC bought a new stake in shares of Sangamo Therapeutics during the third quarter worth $315,000. Cubist Systematic Strategies LLC increased its position in shares of Sangamo Therapeutics by 143.9% during the third quarter. Cubist Systematic Strategies LLC now owns 19,942 shares of the biopharmaceutical company’s stock worth $299,000 after acquiring an additional 11,766 shares in the last quarter. Point72 Asset Management L.P. grew its position in Sangamo Therapeutics by 93.8% in the third quarter. Point72 Asset Management L.P. now owns 693,300 shares of the biopharmaceutical company’s stock valued at $10,400,000 after purchasing an additional 335,595 shares in the last quarter. Jane Street Group LLC bought a new position in Sangamo Therapeutics in the third quarter valued at $624,000. Finally, California State Teachers Retirement System grew its position in Sangamo Therapeutics by 5.0% in the third quarter. California State Teachers Retirement System now owns 132,741 shares of the biopharmaceutical company’s stock valued at $1,991,000 after purchasing an additional 6,360 shares in the last quarter. 63.29% of the stock is owned by institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Analyst Recommendations for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Stock Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related stocks with our FREE daily email newsletter.